These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34129685)

  • 21. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
    Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
    Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wuzhi Tablet (
    Li J; Chen S; Qin X; Fu Q; Bi H; Zhang Y; Wang X; Liu L; Wang C; Huang M
    Drug Metab Dispos; 2017 Nov; 45(11):1114-1119. PubMed ID: 28864749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of CYP3A5 genetic differences in tacrolimus on quantitative interstitial fibrosis and long-term graft function in kidney transplant recipients.
    Komine N; Satoh S; Saito M; Numakura K; Inoue T; Tsuruta H; Narita S; Komatsuda A; Nanjo H; Kagaya H; Niioka T; Miura M; Mitobe Y; Habuchi T
    Int Immunopharmacol; 2018 May; 58():57-63. PubMed ID: 29550576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP3A5 *1 allele associated with tacrolimus trough concentrations but not subclinical acute rejection or chronic allograft nephropathy in Japanese renal transplant recipients.
    Satoh S; Saito M; Inoue T; Kagaya H; Miura M; Inoue K; Komatsuda A; Tsuchiya N; Suzuki T; Habuchi T
    Eur J Clin Pharmacol; 2009 May; 65(5):473-81. PubMed ID: 19125240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of diltiazem on pharmacokinetics of tacrolimus in relation to CYP3A5 genotype status in renal recipients: from retrospective to prospective.
    Li JL; Wang XD; Chen SY; Liu LS; Fu Q; Chen X; Teng LC; Wang CX; Huang M
    Pharmacogenomics J; 2011 Aug; 11(4):300-6. PubMed ID: 20514078
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Composite CYP3A (CYP3A4 and CYP3A5) phenotypes and influence on tacrolimus dose adjusted concentrations in adult heart transplant recipients.
    Liu M; Hernandez S; Aquilante CL; Deininger KM; Lindenfeld J; Schlendorf KH; Van Driest SL
    Pharmacogenomics J; 2024 Feb; 24(2):4. PubMed ID: 38360955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive Capacity of Population Pharmacokinetic Models for the Tacrolimus Dose Requirements of Pediatric Solid Organ Transplant Recipients.
    Pasternak AL; Park JM; Pai MP
    Ther Drug Monit; 2023 Feb; 45(1):95-101. PubMed ID: 36624576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients.
    Warzyszyńska K; Zawistowski M; Karpeta E; Jałbrzykowska A; Kosieradzki M
    Ann Transplant; 2022 Jul; 27():e936276. PubMed ID: 35879888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP3A5 genotype had no impact on intrapatient variability of tacrolimus clearance in renal transplant recipients.
    Spierings N; Holt DW; MacPhee IA
    Ther Drug Monit; 2013 Jun; 35(3):328-31. PubMed ID: 23666583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching Immunosuppression From Cyclosporine to Tacrolimus in Kidney Transplant Recipients Based on CYP3A5 Genotyping.
    Wang X; Yang Y; Liu Z; Xiao C; Gao L; Zhang W; Zhang W; Wang Z
    Ther Drug Monit; 2019 Feb; 41(1):97-101. PubMed ID: 30520827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of tacrolimus intrapatient variability and CYP3A5 polymorphism on the outcomes of pediatric kidney transplantation.
    Choi JS; Ko H; Kim HK; Chung C; Han A; Min SK; Ha J; Kang HG; Ha IS; Min S
    Pediatr Transplant; 2022 Sep; 26(6):e14297. PubMed ID: 35466485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
    Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
    Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.
    Khan AR; Raza A; Firasat S; Abid A
    Pharmacogenomics J; 2020 Aug; 20(4):553-562. PubMed ID: 31902947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies.
    Rojas L; Neumann I; Herrero MJ; Bosó V; Reig J; Poveda JL; Megías J; Bea S; Aliño SF
    Pharmacogenomics J; 2015 Feb; 15(1):38-48. PubMed ID: 25201288
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the CYP3A4*1G polymorphism and its combination with CYP3A5 genotypes on tacrolimus pharmacokinetics in renal transplant patients.
    Miura M; Satoh S; Kagaya H; Saito M; Numakura K; Tsuchiya N; Habuchi T
    Pharmacogenomics; 2011 Jul; 12(7):977-84. PubMed ID: 21635144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation.
    Min S; Papaz T; Lafreniere-Roula M; Nalli N; Grasemann H; Schwartz SM; Kamath BM; Ng V; Parekh RS; Manlhiot C; Mital S
    Pediatr Transplant; 2018 Nov; 22(7):e13285. PubMed ID: 30178515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies.
    Zong YP; Wang ZJ; Zhou WL; Zhou WM; Ma TL; Huang ZK; Zhao CC; Xu Z; Tan RY; Gu M
    World J Pediatr; 2017 Oct; 13(5):421-426. PubMed ID: 28540692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.
    Prytuła AA; Cransberg K; Bouts AH; van Schaik RH; de Jong H; de Wildt SN; Mathôt RA
    Clin Pharmacokinet; 2016 Sep; 55(9):1129-43. PubMed ID: 27138785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.